Yuriy Gankin

Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA.

Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA.

Quantori LLC is an end-to-end digital IT service provider for the life science and healthcare industries. Quantori is based in Cambridge, MA, and the CEO of the company is Richard Golob. The company specializes in providing customized scientific informatics solutions to accelerate target and drug discovery. The company's expertise allows them to automate, analyze, and digitally transform to gain a competitive advantage.

Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA.

Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA.